EyePoint Pharmaceuticals (NASDAQ:EYPT) Receives Buy Rating from Chardan Capital
Chardan Capital reiterated their buy rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $33.00 price objective on the stock. A number of other analysts also recently commented on the stock. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals […]
Chardan Capital reiterated their buy rating on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $33.00 price objective on the stock. A number of other analysts also recently commented on the stock. Citigroup assumed coverage on shares of EyePoint Pharmaceuticals […]
